SPTX
Seaport Therapeutics, Inc.
$18.00
+1.58%
$963.5M
No data for this timeframe.
Vol
Market Cap$963.5M
Cap SizeSmall Cap
Insider Activity1B / 0S
Insider Net $$19.8M
SEC Reports9
Recent Activity
Jun 8, 2026
SEC
Seaport Therapeutics reported Q1 2026 earnings with a net loss of $25.4M ($10.34/share), widening from $13.1M ($5.65/sha
8-K — Impact 4/10
May 7, 2026
SEC
General Atlantic entities filed Form 3 initial beneficial ownership disclosures for Seaport Therapeutics (SPTX), reporti
3 — Impact 3/10
May 4, 2026
Insider
Loebel Antony acquired 20,109 shares
Chief Medical Officer
May 4, 2026
Insider
Loebel Antony disposed of 63,157 shares
Chief Medical Officer
May 4, 2026
Insider
ARCH Venture Partners XII, LLC acquired 2,513,686 shares
10%+ Owner
May 4, 2026
short_interest
FTD: SPTX — 29,083 shares ($0.6M) failed to deliver
Settlement: 20260504, Price: $19.84, FTD Value: $577,006.72, SEAPORT THERAPEUTICS INC COM
May 1, 2026
SEC
Seaport Therapeutics completed its initial public offering of 14,160,000 shares at $18.00 per share, raising $254.9 mill
424B4 — Impact 7/10
Price Targets
$35.00
+94.4% upside
Strong Buy
Current $18.00
Low $30.00
Median $35.00
High $40.00
4 analysts
$30.00
$40.00
Analyst Ratings
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Citigroup | INITIATE | Buy |
| May 26, 2026 | Leerink Partners | INITIATE | Outperform |
| May 26, 2026 | JP Morgan | INITIATE | Overweight |
| May 26, 2026 | Stifel | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.60 | $-0.66 — $-0.56 | 3 | |
| Next Q | $-0.58 | $-0.62 — $-0.55 | 3 | |
| Current FY | $-6.50 | $-12.07 — $-2.96 | 3 | |
| Next FY | $-2.46 | $-3.01 — $-1.71 | 62% YoY | 3 |
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | Loebel Antony | C | $0.00 |
| May 4, 2026 | Loebel Antony | C | $0.00 |
| May 4, 2026 | ARCH Venture | C | $0.00 |
| May 4, 2026 | ARCH Venture | C | $0.00 |
| May 4, 2026 | ARCH Venture | BUY | $19.8M |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
14 unique insiders with 34 transactions. Net insider value: $19.8M ($19.8M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | Loebel Antony | Chief Medical Officer | CONVERT | 20,109 | — | — |
| May 4, 2026 | Loebel Antony | Chief Medical Officer | CONVERT | 63,157 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10%+ Owner | CONVERT | 2,513,686 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10%+ Owner | CONVERT | 2,513,686 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10%+ Owner | BUY | 1,100,000 | $18.00 | $19.8M |
| May 4, 2026 | ARCH Venture Partners XII, LLC | 10%+ Owner | CONVERT | 2,681,265 | — | — |
| May 4, 2026 | PAUL STEVEN M | Director | CONVERT | 67,031 | — | — |
| May 4, 2026 | PAUL STEVEN M | Director | CONVERT | 210,526 | — | — |
| May 4, 2026 | Torres Denice | Director | CONVERT | 42,105 | — | — |
| May 4, 2026 | Torres Denice | Director | CONVERT | 13,406 | — | — |
| May 4, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | CONVERT | 10,526 | — | — |
| May 4, 2026 | Gladstein Lana | General Counsel | CONVERT | 33,515 | — | — |
| May 4, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | CONVERT | 3,351 | — | — |
| May 4, 2026 | Gladstein Lana | General Counsel | CONVERT | 105,263 | — | — |
| May 4, 2026 | White Lauren | Chief Financial Officer | CONVERT | 6,702 | — | — |
| May 4, 2026 | White Lauren | Chief Financial Officer | CONVERT | 21,052 | — | — |
| May 4, 2026 | HEALY JAMES | Director | CONVERT | 1,927,159 | — | — |
| May 4, 2026 | HEALY JAMES | Director | CONVERT | 6,052,631 | — | — |
| May 4, 2026 | HEALY JAMES | Director | CONVERT | 2,526,315 | — | — |
| May 4, 2026 | PureTech Health plc | 10%+ Owner | CONVERT | 12,736,014 | — | — |
| May 4, 2026 | PureTech Health plc | 10%+ Owner | CONVERT | 40,000,000 | — | — |
| May 4, 2026 | PureTech Health plc | 10%+ Owner | CONVERT | 8,421,052 | — | — |
| May 4, 2026 | PureTech Health plc | 10%+ Owner | CONVERT | 3,031,578 | — | — |
| Apr 30, 2026 | Mates Sharon | Director | AWARD | 49,033 | — | — |
| Apr 30, 2026 | Loebel Antony | Chief Medical Officer | AWARD | 63,680 | — | — |
| Apr 30, 2026 | HOMBACH ROBERT J. | Director | AWARD | 12,258 | — | — |
| Apr 30, 2026 | PAUL STEVEN M | Director | AWARD | 12,258 | — | — |
| Apr 30, 2026 | Torres Denice | Director | AWARD | 12,258 | — | — |
| Apr 30, 2026 | Gladstein Lana | General Counsel | AWARD | 63,680 | — | — |
| Apr 30, 2026 | Chen Michael Cunyuan | Chief Scientific Officer | AWARD | 63,680 | — | — |
| Apr 30, 2026 | PETERSON SANDRA E | Director | AWARD | 12,258 | — | — |
| Apr 30, 2026 | Wheadon David E. | Director | AWARD | 12,258 | — | — |
| Apr 30, 2026 | White Lauren | Chief Financial Officer | AWARD | 63,680 | — | — |
| Apr 30, 2026 | Zohar Daphne | Chief Executive Officer | AWARD | 271,813 | — | — |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 7 neutral. Avg impact: 3.6/10.
NEUTRAL
8-K
4/10
Seaport Therapeutics reported Q1 2026 earnings with a net loss of $25.4M ($10.34/share), widening fr
Jun 8, 2026
NEUTRAL
3
3/10
General Atlantic entities filed Form 3 initial beneficial ownership disclosures for Seaport Therapeu
May 7, 2026
BULLISH
424B4
7/10
Seaport Therapeutics completed its initial public offering of 14,160,000 shares at $18.00 per share,
May 1, 2026
NEUTRAL
3
2/10
CEO Daphne Zohar and director Sandra E. Peterson filed initial beneficial ownership statements (Form
May 1, 2026
NEUTRAL
3
2/10
Three insiders at Seaport Therapeutics (SPTX) — CFO Lauren White, director Denice Torres, and direct
May 1, 2026
NEUTRAL
3
2/10
Jason Pitts, Ph.D., filed a Form 3 initial statement of beneficial ownership upon becoming a directo
May 1, 2026
NEUTRAL
3
2/10
Three directors of Seaport Therapeutics (SPTX) filed initial statements of beneficial ownership (For
May 1, 2026
NEUTRAL
3
2/10
Two initial statements of beneficial ownership (Form 3) were filed for Seaport Therapeutics (SPTX) b
May 1, 2026
BULLISH
S-1/A
8/10
Seaport Therapeutics is an IPO for a clinical-stage biotech company developing novel neuropsychiatri
Apr 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Analyst Price Targets
$35.00 mean target
+94.4% upside
Strong Buy (1.25)
$30.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $18.00 |
| Target Low | $30.00 |
| Target Mean | $35.00 |
| Target Median | $35.00 |
| Target High | $40.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.60 | $-0.66 | $-0.56 | — | — | — | $0.0B | — | 3 |
| Next Q 2026-09-30 |
$-0.58 | $-0.62 | $-0.55 | — | — | — | $0.0B | — | 3 |
| Current FY 2026-12-31 |
$-6.50 | $-12.07 | $-2.96 | — | — | — | $0.0B | — | 3 |
| Next FY 2027-12-31 |
$-2.46 | $-3.01 | $-1.71 | 62.1% | — | — | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-3.883 | |
| 7d ago | $0.000 | -3.883 |
| 30d ago | $0.000 | -3.883 |
| 60d ago | $0.000 | -3.883 |
| 90d ago | $0.000 | -3.883 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Citigroup | INITIATE | — | Buy |
| May 26, 2026 | Leerink Partners | INITIATE | — | Outperform |
| May 26, 2026 | JP Morgan | INITIATE | — | Overweight |
| May 26, 2026 | Stifel | INITIATE | — | Buy |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 4, 2026
short_interest
FTD: SPTX — 29,083 shares ($0.6M) failed to deliver
Settlement: 20260504, Price: $19.84, FTD Value: $577,006.72, SEAPORT THERAPEUTICS INC COM